دورية أكاديمية
Omentum: Friend or foe in ovarian cancer immunotherapy?
| العنوان: | Omentum: Friend or foe in ovarian cancer immunotherapy? |
|---|---|
| المؤلفون: | Bella Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. Electronic address: abellacarre@unav.es., Arrizabalaga L; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Fernández-Sendin M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Russo-Cabrera JS; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Translational Oncology Group, Program in Solid Tumors, Cima Universidad de Navarra, Pamplona, Spain; Department of Immunology and Immunotherapy, Clinica Universidad de Navarra, Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. Electronic address: faranda@unav.es. |
| المصدر: | International review of cell and molecular biology [Int Rev Cell Mol Biol] 2022; Vol. 371, pp. 117-131. Date of Electronic Publication: 2022 Jun 27. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101475846 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1937-6448 (Print) Linking ISSN: 19376448 NLM ISO Abbreviation: Int Rev Cell Mol Biol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam : Elsevier |
| مواضيع طبية MeSH: | Ovarian Neoplasms*/pathology , Ovarian Neoplasms*/surgery , Peritoneal Neoplasms*/pathology , Peritoneal Neoplasms*/therapy, Female ; Humans ; Immunologic Factors ; Immunotherapy ; Omentum/pathology ; Omentum/surgery |
| مستخلص: | Ovarian cancer often spreads out of the ovary before a patient is diagnosed and is the deadliest gynecological malignancy. The aggressiveness of ovarian cancer is determined by the progression in the form of peritoneal carcinomatosis, a stage with a poor prognosis and an untreatable condition in most patients. One of the first tumor nests or the origin of metastasis in the peritoneal cavity is the omentum. The omentum contains immune aggregates, called milky spots, embedded in adipose tissue, which support tumor growth by various mechanisms, including immunosuppressive immune cells and metabolic functions. In this sense, the abundance of blood vessels, omental resident macrophages, and chemokines, among other factors, are known to promote invasiveness, proliferation and resistance to cancer therapies. As a result, surgical practice employed in advanced-stage ovarian cancer almost constantly includes omentectomy. Paradoxically, the omentum is considered the "abdominal policeman" that contributes to peritoneal immunity by capturing antigens and pathogens from the peritoneal cavity and promoting effective immune responses against microbes. Why immunosurveillance against the metastatic tumor does not take place in the omentum? Could omental immune responses be activated with immunotherapeutic interventions? The omentum has largely been ignored in cancer immunology and immunotherapy, and the potential translational implications of this in ovarian cancer are still unclear. Here, we focus on the dual role of the omentum in ovarian cancer: its role in antitumor immune responses versus its activities fostering cancer progression. (Copyright © 2022 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Cancer immunotherapy; Omentum; Ovarian cancer; Peritoneal carcinomatosis; Tumor microenvironment |
| المشرفين على المادة: | 0 (Immunologic Factors) |
| تواريخ الأحداث: | Date Created: 20220814 Date Completed: 20220816 Latest Revision: 20220825 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/bs.ircmb.2022.04.017 |
| PMID: | 35964998 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1937-6448 |
|---|---|
| DOI: | 10.1016/bs.ircmb.2022.04.017 |